TrialThe oncologist2025

A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.

Subotheni Thavaneswaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.